Abelson Joel E 4
4 · Talecris Biotherapeutics Holdings Corp. · Filed Aug 26, 2010
Insider Transaction Report
Form 4
Abelson Joel E
Sr VP & GM, Int'l Bus.
Transactions
- Sale
Common Stock
2010-08-25$21.89/sh−105,440$2,308,008→ 14,049 total - Exercise/Conversion
Options (right to buy)
2010-08-25$11.00/sh−105,440$1,159,840→ 0 totalExercise: $11.00From: 2007-04-01Exp: 2016-12-06→ Common Stock (105,440 underlying) - Exercise/Conversion
Common Stock
2010-08-25$11.00/sh+105,440$1,159,840→ 119,489 total
Holdings
- 186,360
Options (right to buy)
Exercise: $11.00From: 2009-04-01Exp: 2018-04-01→ Common Stock (186,360 underlying) - 11,755
Options (right to buy)
Exercise: $19.00Exp: 2019-09-30→ Common Stock (11,755 underlying)
Footnotes (5)
- [F1]The transaction reported was effected purusant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2010.
- [F2]The number of shares reported includes restricted share units representing the right to receive 5,921 shares of the Issuers common stock that will vest in three equal annual installments beginning April 1, 2011, as detailed in a restricted share unit award agreement by and between the Issuer and the Reporting Person, dated as of September 30, 2009.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.81 to $21.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The option is fully vested and immediately exercisable.
- [F5]Option will vest in three equal annual installments beginning April 1, 2011, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of September 30, 2009.